NCT02475577

Brief Summary

The study will test a hypothesis that the remote monitoring with text and email alerts sent to study subject and optional family/other caregiver (Intervention 1) will have a higher return on investment compared to remote monitoring with nurse researcher follow-up telephone communication to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts) (Intervention 2) and self-monitoring without intervention (Control).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
163

participants targeted

Target at P50-P75 for not_applicable heart-failure

Timeline
Completed

Started Jun 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

June 12, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 18, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
Last Updated

March 31, 2016

Status Verified

March 1, 2016

Enrollment Period

2 years

First QC Date

June 12, 2015

Last Update Submit

March 29, 2016

Conditions

Keywords

telemedicineheart failurehome blood pressure monitoring

Outcome Measures

Primary Outcomes (1)

  • Number of subjects with unplanned re- hospitalization (heart failure-related and other hospitalization)

    31 days post discharge with a heart failure-related hospital re-hospitalization.

    31 days

Secondary Outcomes (6)

  • Communication with healthcare provider or emergency department

    31 days

  • Number of non-conformity issues

    31 days

  • Health-related quality of life Questionnaire

    31 days

  • Subject satisfaction Questionnaire

    31 days

  • Physician satisfaction Questionnaire

    31 days

  • +1 more secondary outcomes

Other Outcomes (2)

  • Number and type of incidents

    31 days

  • Subject attrition

    31 days

Study Arms (3)

Control

EXPERIMENTAL

Control: Peripherals with HealthInterlink technology will record and transmit data, without intervention. Subject is able to view graphed data, bring the HealthInterlink tablet/smartphone to the physician's office and share data with family/other caregiver.

Device: Peripherals with HealthInterlink technology

Intervention 1

EXPERIMENTAL

Intervention 1: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver.

Device: Peripherals with HealthInterlink technology

Intervention 2

EXPERIMENTAL

Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.

Device: Peripherals with HealthInterlink technology

Interventions

home remote monitoring

Also known as: Welch Allyn, Blood Pressure monitor, Weight Scale, Pulse Oximeter, tablet/smartphone-based technology
ControlIntervention 1Intervention 2

Eligibility Criteria

Age18 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Absence of significant vision, hearing, or other communication deficits
  • English speaking;
  • Capable and willing to give informed consent;
  • Participated in the in-patient heart failure class within the last three months. Acceptable candidate for elective, non-emergent, remote monitoring as determined by ordering physician;
  • Living in a private home;
  • Hospital admission for Heart Failure or decompensation in the previous 12 months
  • New York Heart Association (NYHA) classes II-IV, as assigned by the nurse researcher, trained by a cardiologist
  • Cardiac aetiology: ischaemic, idiopathic, hypertensive, or valvular
  • Left ventricular ejection fraction \<40% s an index of systolic dysfunction, combined or not with a left ventricular filling pattern supporting the presence of diastolic dysfunction, according to the American College of Cardiology/American Heart Association Guidelines for chronic heart failure.
  • NYHA class II-III who had an ejection fraction \>40% and evidence of diastolic left ventricular dysfunction.
  • Optional subject with a diagnosis of diabetes (indicated by HbA1c \>7).

You may not qualify if:

  • Currently involved in other investigational clinical trials (unless permission is granted by other study PI);
  • Females who are pregnant, planning to become pregnant within 3 months, or lactating;
  • Requirement for emergent placement other than private home (subject's condition would be compromised if there is a delay in placement).
  • Myocardial infarction, revascularization or Implantable Cardioverter Defibrillator (ICD) implantation in the previous 6 months angina or objective myocardial ischaemia requiring future revascularization implanted ventricular or atrial pacemaker (except dual chamber ICD pacemakers with good sinus activity);
  • End-stage heart failure requiring regular inotropic drug infusions;
  • Chronic renal failure requiring dialysis treatment and
  • Unstable angina.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NCH Healthcare System

Naples, Florida, 34102, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Heart Failure

Interventions

Blood Pressure Monitors

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

SphygmomanometersDiagnostic EquipmentEquipment and Supplies

Study Officials

  • Theresa Morrison, PhD

    NCH Healthcare System Inc

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Theresa Morrison, PhD

CONTACT

Laurie Zone-Smith, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2015

First Posted

June 18, 2015

Study Start

June 1, 2015

Primary Completion

June 1, 2017

Study Completion

August 1, 2017

Last Updated

March 31, 2016

Record last verified: 2016-03

Locations